Published in Epilepsy Res on November 12, 2008
Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov (2010) 2.22
Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol (2010) 1.27
Neuronal voltage-gated ion channels are genetic modifiers of generalized epilepsy with febrile seizures plus. Neurobiol Dis (2010) 1.23
Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics (2009) 1.09
Enhancing m currents: a way out for neuropathic pain? Front Mol Neurosci (2009) 0.93
Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications. Pharmaceuticals (Basel) (2010) 0.86
Ion channels as drug targets in central nervous system disorders. Curr Med Chem (2013) 0.84
New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord (2010) 0.84
Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clin Pharmacol (2010) 0.83
Anticonvulsant activity of 2,4(1H)-diarylimidazoles in mice and rats acute seizure models. Bioorg Med Chem (2010) 0.83
Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol (2011) 0.83
Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs (2009) 0.82
Hypothesis: the role of sterols in autism spectrum disorder. Autism Res Treat (2011) 0.81
Activation of peripheral KCNQ channels attenuates inflammatory pain. Mol Pain (2014) 0.81
Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy. Drug Healthc Patient Saf (2012) 0.80
Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr Dis Treat (2011) 0.80
Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.78
Add-on Effect of Levetiracetam on Cognitive Activity of Carbamazepine and Topiramate Treated Healthy Rats. J Clin Diagn Res (2015) 0.78
Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults. J Cent Nerv Syst Dis (2013) 0.77
Clinical utility of adjunctive retigabine in partial onset seizures in adults. Ther Clin Risk Manag (2012) 0.77
Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther (2015) 0.77
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. CNS Drugs (2016) 0.76
Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology (Berl) (2009) 0.76
New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapy. J Epilepsy Res (2011) 0.75
Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going? Pharmaceuticals (Basel) (2010) 0.75
Synthesis and anticonvulsant activity of new N-phenyl-2-(4-phenylpiperazin-1-yl)acetamide derivatives. Med Chem Res (2015) 0.75
Update on treatment of partial onset epilepsy: role of eslicarbazepine. Neuropsychiatr Dis Treat (2010) 0.75
Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat (2015) 0.75
Natural Products in Epilepsy-the Present Situation and Perspectives for the Future. Pharmaceuticals (Basel) (2010) 0.75
An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R D (2016) 0.75
Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability. Neurochem Res (2017) 0.75
Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide. Neurochem Res (2017) 0.75
ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2009) 7.03
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol (2011) 3.93
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 3.69
Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia (2011) 3.48
Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol (2013) 3.06
Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia (2008) 2.74
Unifying the definitions of sudden unexpected death in epilepsy. Epilepsia (2011) 2.24
Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov (2010) 2.22
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 2.20
A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet (2009) 2.12
Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia (2002) 1.91
Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia (2002) 1.82
International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia (2013) 1.82
Valproate: past, present, and future. CNS Drug Rev (2003) 1.77
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol (2003) 1.76
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol (2009) 1.73
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2013) 1.69
Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 1.56
Vigabatrin and epilepsy: lessons learned. Epilepsia (2007) 1.55
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Mortality of epilepsy in developed countries: a review. Epilepsia (2005) 1.44
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. Epilepsia (2015) 1.40
Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia (2009) 1.38
[The prescription registry and abuse of pregabalin]. Tidsskr Nor Laegeforen (2011) 1.37
Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: reply to Beyenburg et al., 2009. Epilepsia (2010) 1.37
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35
Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization. J Physiol (2008) 1.35
Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology (2012) 1.32
Seizures following picornavirus infection. Epilepsia (2008) 1.31
The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res (2006) 1.30
Risk factors for suicide in epilepsy: a case control study. Epilepsia (2002) 1.29
Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia (2011) 1.27
Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. Epilepsia (2009) 1.26
Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models. Epilepsy Res (2010) 1.25
A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons. J Neurosci (2006) 1.24
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24
Discovery of antiepileptic drugs. Neurotherapeutics (2007) 1.24
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res (2006) 1.23
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia (2007) 1.23
The pharmacological treatment of epilepsy in adults. Lancet Neurol (2011) 1.22
Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol (2011) 1.22
Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res (2007) 1.20
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol (2003) 1.20
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia (2011) 1.20
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia (2007) 1.19
Oral contraceptives reduce lamotrigine plasma levels. Neurology (2003) 1.18
Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold. Hum Mol Genet (2003) 1.17
Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia (2002) 1.17
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia (2004) 1.16
Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit (2003) 1.15
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet (2006) 1.14
Development of postinfection epilepsy after Theiler's virus infection of C57BL/6 mice. J Neuropathol Exp Neurol (2010) 1.14
Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol Ther (2009) 1.10
Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol (2009) 1.10
EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia (2004) 1.07
Revisiting phenobarbital for epilepsy. BMJ (2004) 1.07
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia (2013) 1.07
Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res (2004) 1.07
Epilepsy after head injury. Curr Opin Neurol (2004) 1.06
Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia (2007) 1.06
Theiler's virus infection chronically alters seizure susceptibility. Epilepsia (2009) 1.05
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res (2004) 1.05
Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia (2002) 1.05
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia (2012) 1.04
Comment on epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia (2005) 1.03
Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem (2008) 1.02
The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia (2012) 1.01
Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res (2003) 1.01
Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. J Neurotrauma (2004) 0.99
Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia (2010) 0.99
Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav (2004) 0.99
Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem (2008) 0.98
Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. Adv Drug Deliv Rev (2011) 0.98
New and forthcoming anti-epileptic drugs. Curr Opin Neurol (2011) 0.97
Management of epilepsy during pregnancy. Drugs (2007) 0.97